. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: Trop Med Int Health. 2014 Jul 8;19(9):1057–1067. doi: 10.1111/tmi.12352

Table 1.

Characteristics of studies and children included in the systematic review and meta-analysis of cotrimoxazole prophylactic treatment (CPT) and malaria incidence or mortality.

Author (year)	Country (Setting)	Pfpr	Months of fup	Design	CPT regimen	Children in CPT group			Children in control group			Adherence monitoring
Author (year)	Country (Setting)	Pfpr	Months of fup	Design	CPT regimen	No.	Age (years)	HIV status	No.	Age (years)	HIV sta- tus	Adherence monitoring
Malaria incidence
Thera (2005)	Mali (rural)	0.49	3	RCT	TMP 150 mg/m2 SMX 750 mg/m2 Thrice-weekly	160	10 (2.9)	Healthy children	80	10 (2.8)	Healthy children	No
Gasasira (2010)	Uganda (urban)	0.20	28	Cohort	Once-daily	292	6.0 (2.6)	HIV- infected	517	7.4 (2.7)	Healthy children	Yes (self-reported)
Sandison (2011)	Uganda (rural)	0.38	24	RCT	TMP 40–80 mg/kg SMX 200–400 mg/kg Once-daily	90	9.6 (8.3–12.4)	HIV- exposed	80	10.0 (8.9–13.5)	HIV-exposed	Yes (self-reported)
Dow (2012)	Malawi (urban)	0.34	6	Cohort	TMP 40mg/kg SMX 200mg/kg	1239	NR	HIV-exposed	283	NR	HIV-exposed	No
Ezeamama (2012)	Tanzania (urban)	0.07	27	Cohort	NR	^*	NR	HIV-infected and HIV-exposed	^*	NR	HIV-infected and HIV-exposed	Yes (self-reported)
Mortality
Chintu (2004)	Zambia (urban)	0.07	18.9	RCT	TMP 40–80 mg SMX 200–400 mg Once-daily	265	4.2 (2.8–8.3)	HIV- infected	269	4.5 (2.1–8.2)	HIV-infected	No
Desmonde (2011)	Cote d'Ivoire (urban)	0.68	12	Cohort	NR	271	NR	HIV- infected	134	NR	HIV-infected	No

NR, not reported; RCT, randomized controlled trial, Pfpr: annualized parasite prevalence in children 2–10 years of age in X-survey

The study by Ezeamama et al included 255 HIV-infected and 2043 HIV-exposed uninfected children. Cotrimoxazole prophylaxis was analyzed as a time-varying covariate, based on whether or not the mother reported giving cotrimoxazole to her child over the past month.